Analysts Set Expectations for Arvinas, Inc.’s Q4 2022 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVNGet Rating) – Equities research analysts at Jefferies Financial Group reduced their Q4 2022 EPS estimates for shares of Arvinas in a research report issued on Monday, November 21st. Jefferies Financial Group analyst A. Tewari now anticipates that the company will post earnings of $0.03 per share for the quarter, down from their prior estimate of $0.09. The consensus estimate for Arvinas’ current full-year earnings is ($4.67) per share.

Arvinas (NASDAQ:ARVNGet Rating) last posted its earnings results on Tuesday, November 8th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.26). Arvinas had a negative return on equity of 36.12% and a negative net margin of 225.34%. The business had revenue of $30.30 million during the quarter, compared to the consensus estimate of $44.20 million.

A number of other research firms also recently weighed in on ARVN. Cantor Fitzgerald reduced their target price on shares of Arvinas from $106.00 to $90.00 in a report on Wednesday. Piper Sandler lifted their price target on shares of Arvinas from $76.00 to $81.00 and gave the stock an “overweight” rating in a research note on Tuesday. Citigroup dropped their price target on shares of Arvinas from $103.00 to $88.00 in a research note on Thursday, August 18th. Truist Financial dropped their price target on shares of Arvinas from $170.00 to $100.00 in a research note on Wednesday. Finally, Capital One Financial began coverage on shares of Arvinas in a research note on Tuesday, October 25th. They set an “overweight” rating for the company. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $79.19.

Arvinas Stock Down 2.8 %

Arvinas stock opened at $39.56 on Wednesday. The company’s 50-day moving average price is $45.35 and its 200-day moving average price is $45.79. Arvinas has a twelve month low of $34.90 and a twelve month high of $83.40. The company has a market cap of $2.11 billion, a PE ratio of -8.31 and a beta of 1.89.

Institutional Trading of Arvinas

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC boosted its position in Arvinas by 2.3% during the 2nd quarter. FMR LLC now owns 7,363,193 shares of the company’s stock valued at $309,917,000 after acquiring an additional 167,390 shares in the last quarter. Vanguard Group Inc. boosted its position in Arvinas by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,180,065 shares of the company’s stock valued at $185,971,000 after acquiring an additional 116,877 shares in the last quarter. BlackRock Inc. boosted its position in Arvinas by 0.9% during the 3rd quarter. BlackRock Inc. now owns 3,706,508 shares of the company’s stock valued at $164,901,000 after acquiring an additional 31,339 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Arvinas by 5.2% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,267,570 shares of the company’s stock valued at $137,532,000 after acquiring an additional 160,860 shares in the last quarter. Finally, Bellevue Group AG boosted its position in Arvinas by 3.1% during the 3rd quarter. Bellevue Group AG now owns 2,190,762 shares of the company’s stock valued at $97,467,000 after acquiring an additional 66,486 shares in the last quarter. Institutional investors own 91.20% of the company’s stock.

About Arvinas

(Get Rating)

Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.

See Also

Earnings History and Estimates for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.